BÜHLMANN fCAL® ELISA Citation Manz, M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012 Jan 10;12:5. doi: 10.1186/1471-230X-12-5. “All together, those results support the concept that fecal calprotectin is a useful marker in
Continue Reading →
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
BÜHLMANN fCAL® ELISA Citation Burri E, Manz M., Rothen C, Rossi L,Beglinger C, Lehmann S. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clinica Chimica Acta. 2013 Feb; 416: 41-47. doi: 10.1016/j.cca.2012.11.008 “…we demonstrated, that the diagnostic accuracy of monoclonal
Continue Reading →
Quantum Blue® fCAL Citation Labaere, D, Smismans A, Olmen A, Christiaens P, D’Haens G, Moons V, Cuyle P, Frans J, and Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease, United European Gastroenterology J. 2014 Feb; 2(1): 30–37. doi: 10.1177/2050640613518201 "The EliA [Phadia] cut off for diagnosis was optimal at a level of 15 mg/g. This is as low as
Continue Reading →
Value of Fecal Calprotectin in the Diagnosis of IBD: Edouard, Louis. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. Journal of Crohn's and Colitis, 2015, 1–3 doi:10.1093/ecco-jcc/jju012. “…fecal calprotectin as a unique first line test would be sufficient to decide in which patient to perform further endoscopic or medical imaging
Continue Reading →
Social Links